Dr Reddy’s Posts Surprise Q3 Loss But Strong Operating Results Boost Shares
Main Markets Strong But Compliance Issues Linger
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge for its generic NuvaRing contraceptive but the company’s shares jumped on a robust underlying performance that analysts praised as a "great set of numbers."
